Clinical Trial Update: Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating chemoradiation plus tislelizumab for conversion therapy in locally nonresectable esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Jiangsu Cancer Institute & Hospital | Conditions: Esophageal Squamous Cell Carcinoma, Tislelizumab | Phase 1, Phase 2 | Status: UNKNOWN